{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:43:49Z","timestamp":1782603829169,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are an integral antitumor therapy for many malignancies. Most patients show very good tolerability to ICIs; however, serious immune-related adverse events (irAEs) with ICIs have been well documented and prevent some patients from continuing ICIs or even become the direct cause of patient death. Cytopenia is a rare irAE but can be life-threatening. Here, we present the case of a 66-year-old male patient with metastatic lung adenocarcinoma who received two doses of chemotherapy + PD-1 antibody tislelizumab and developed pancytopenia after each dose. Although the first episode of pancytopenia resolved with a treatment regimen of granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), and red blood cell and platelet transfusion, the second episode showed extreme resistance to these treatments and improved only after the administration of steroids. His second pancytopenia episode resolved after a long course of treatment with methylprednisolone, G-CSF, TPO, hetrombopag and multiple red blood cell and platelet transfusions. However, he suffered a cerebral infarction when his platelet count was in the normal range and gradually recovered 1 week later. This case highlights the importance of the early recognition and management of hematological irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1148425","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T10:36:47Z","timestamp":1690281407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Hang-Yu","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Nan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Ming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.530478","article-title":"Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: case report and literature review","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205030","article-title":"Immune checkpoint inhibitor-related cytopenias: about 68 cases from the french pharmacovigilance database","volume":"14","author":"Martin","year":"2022","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.765608","article-title":"Grade 4 neutropenia secondary to immune checkpoint inhibition - A descriptive observational retrospective multicenter analysis","volume":"11","author":"Zaremba","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother CII"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7812\/TPP\/17-004","article-title":"Pembrolizumab-induced pancytopenia: A case report","volume":"21","author":"Atwal","year":"2017","journal-title":"Permanente J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000500856","article-title":"AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: A case report","volume":"12","author":"Ni","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000504130","article-title":"Immune-related pancytopenia induced by anti-PD-1 therapy - interrupt or continue treatment - the role of immunohistochemical examination","volume":"12","author":"Cybulska-Stopa","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13582","article-title":"Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer","volume":"11","author":"Ueki","year":"2020","journal-title":"Thorac Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-related bone marrow failure following anti-PD1 therapy","volume":"80","author":"Michot","year":"2017","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.02.018","article-title":"Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma","volume":"119","author":"Tokumo","year":"2018","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15341","article-title":"Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary","volume":"47","author":"Uehara","year":"2020","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00454","article-title":"Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia","volume":"10","author":"Calvo","year":"2019","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000232","article-title":"Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma","volume":"26","author":"Kong","year":"2016","journal-title":"Melanoma Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2021.00899","article-title":"Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report","volume":"38","author":"Baek","year":"2021","journal-title":"Yeungnam Univ J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13256-019-2245-y","article-title":"Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Hasegawa","year":"2019","journal-title":"J Med Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3439","article-title":"Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: A case report","volume":"12","author":"Li","year":"2016","journal-title":"Exp Ther Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.11.026","article-title":"A case of multiple cerebral infarction preceding acute exacerbation of idiopathic thrombocytopenic purpura","volume":"28","author":"Sasaki","year":"2019","journal-title":"J stroke Cerebrovasc Dis Off J Natl Stroke Assoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2016.12.013","article-title":"A case of heparin-induced thrombocytopenia with subacute stent thrombosis, multiple cerebral infarction, and acute limb ischemia","volume":"15","author":"Suzuki","year":"2017","journal-title":"J Cardiol Cases"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1148425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T10:36:54Z","timestamp":1690281414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1148425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2023.1148425"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1148425","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"article-number":"1148425"}}